AU501581B2 - Phenol ethers - Google Patents

Phenol ethers

Info

Publication number
AU501581B2
AU501581B2 AU19259/76A AU1925976A AU501581B2 AU 501581 B2 AU501581 B2 AU 501581B2 AU 19259/76 A AU19259/76 A AU 19259/76A AU 1925976 A AU1925976 A AU 1925976A AU 501581 B2 AU501581 B2 AU 501581B2
Authority
AU
Australia
Prior art keywords
phenol ethers
ethers
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU19259/76A
Other languages
English (en)
Other versions
AU1925976A (en
Inventor
P M J Manoury
I A G Cavero
H Najer
D P R L Giudicelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9162099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU501581(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of AU1925976A publication Critical patent/AU1925976A/en
Application granted granted Critical
Publication of AU501581B2 publication Critical patent/AU501581B2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU19259/76A 1975-11-06 1976-11-02 Phenol ethers Expired AU501581B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533899A FR2330383A1 (fr) 1975-11-06 1975-11-06 Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment

Publications (2)

Publication Number Publication Date
AU1925976A AU1925976A (en) 1978-05-11
AU501581B2 true AU501581B2 (en) 1979-06-21

Family

ID=9162099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19259/76A Expired AU501581B2 (en) 1975-11-06 1976-11-02 Phenol ethers

Country Status (24)

Country Link
US (2) US4252984A (en:Method)
JP (1) JPS5848543B2 (en:Method)
AR (1) AR214303A1 (en:Method)
AT (1) AT344683B (en:Method)
AU (1) AU501581B2 (en:Method)
BE (1) BE847801A (en:Method)
CA (1) CA1072981A (en:Method)
CH (1) CH602582A5 (en:Method)
DE (1) DE2649605C3 (en:Method)
DK (1) DK145119C (en:Method)
ES (1) ES452920A1 (en:Method)
FI (1) FI62829C (en:Method)
FR (1) FR2330383A1 (en:Method)
GB (1) GB1515978A (en:Method)
GR (1) GR61363B (en:Method)
IE (1) IE43645B1 (en:Method)
IL (1) IL50814A (en:Method)
LU (1) LU76117A1 (en:Method)
NL (1) NL179051C (en:Method)
NO (1) NO142034C (en:Method)
NZ (1) NZ182498A (en:Method)
PT (1) PT65780B (en:Method)
SE (1) SE433208B (en:Method)
ZA (1) ZA766338B (en:Method)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2409980A1 (fr) * 1977-11-24 1979-06-22 Synthelabo Ethers de phenols et leur application en therapeutique
IT1147311B (it) * 1980-02-13 1986-11-19 Stabil Bioterapico Farmachim Eteri basici di 4-idrossi-benzofenoni con attivita' quali agenti betabloccanti e relativi procedimento di preparazione
ZW9881A1 (en) * 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
DE3125870C2 (de) * 1980-07-09 1994-09-15 William John Louis 3-Aminopropoxyphenyl Derivate, ihre Herstellung und sie enthaltende Arzneimittel
CH643527A5 (en) * 1980-10-24 1984-06-15 Ciba Geigy Ag Process for the preparation of 1-alkylamino-3-(4-(2-lower alkoxy-ethyl)phenoxy)-2-propanols
FI76551C (fi) 1980-11-06 1988-11-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-aminopropoxifenylderivat.
JPS57108047A (en) * 1980-11-06 1982-07-05 Sandoz Ag 3-aminopropoxyphenyl derivative, manufacture and pharmaceutical composition containing same
US5347050A (en) * 1980-11-06 1994-09-13 Richard Berthold 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
FR2512443A1 (fr) * 1981-09-10 1983-03-11 Synthelabo Derives de phenoxy-3 propanol-2, leur preparation et leur application en therapeutique
DE3151201A1 (de) * 1981-12-23 1983-07-28 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte
US4450172A (en) * 1982-03-10 1984-05-22 E. I. Du Pont De Nemours And Company Antihypertensive polyhalohydroxyisopropyl phenylalka(e)noic acid esters of alkylaminohydroxypropyloxyphenylalkyl alcohols
FR2536390B1 (fr) * 1982-11-22 1986-03-21 Synthelabo Isomere s du betaxolol, sa preparation et son application en therapeutique
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
NZ211815A (en) * 1984-05-15 1988-11-29 Warner Lambert Co Preparation of 1-((3,4-dimethoxyphenethyl)amino)-3- (3-tolyloxy)-2-propanol
GB8412864D0 (en) * 1984-05-19 1984-06-27 Smith Kline French Lab Chemical compounds
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
ES8609190A1 (es) * 1985-02-07 1986-07-16 Pharma Investi S A Un procedimiento para preparar eteres fenolicos
US5095151A (en) * 1985-05-21 1992-03-10 American Home Products Corporation Preparation of propranolol hydrochloride macrocrystals
EP0252007A3 (en) * 1986-06-28 1989-07-05 Ciba-Geigy Ag 2-propanol derivatives as corrosion inhibitors
US4694022A (en) * 1986-12-24 1987-09-15 Alcon Laboratories, Inc. Fatty acid salts of betaxolol useful in the treatment of glaucoma
EP0300290B1 (de) * 1987-07-21 1991-12-18 F. Hoffmann-La Roche Ag Phenoxypropanolamine
FR2672594B1 (fr) * 1991-02-08 1994-07-01 Synthelabo Derives d'ethers de phenols, leur preparation et leur application en therapeutique.
EP0937030B1 (en) * 1995-10-10 2004-03-31 William John Louis 3-amino-propoxyphenyl derivatives (i)
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
US5942633A (en) * 1996-06-19 1999-08-24 Abbott Laboratories Process for the selective alkylation of betaxolol intermediates
US5731463A (en) * 1996-09-23 1998-03-24 Abbott Laboratories Selective alkylation of an alcohol substituted phenol compound
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
DE60006584T2 (de) * 1999-11-30 2004-09-30 Alcon, Inc. Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
DE60120982T2 (de) * 2000-07-27 2007-02-08 Pharmacia Corp. Kombinationstherapie mit epoxy-steroidalem Aldosteronantagonist und beta-adrenergischem Antagonist zur Behandlung von kongestivem Herzversagen
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
HRP20050163A2 (en) 2002-08-19 2005-06-30 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
CN1300079C (zh) * 2004-12-03 2007-02-14 南京大学 合成4-[2-(环丙基甲氧基)乙基]苯酚的新工艺
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体
US9782488B2 (en) 2007-03-12 2017-10-10 Nektar Therapeutics Oligomer-beta blocker conjugates
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
JP2009040769A (ja) * 2008-07-09 2009-02-26 William John Louis 3−アミノ−プロポキシフェニル誘導体(i)
CN104208718B (zh) 2009-02-20 2017-12-29 2-Bbb医疗股份有限公司 基于谷胱甘肽的药物递送系统
KR20190116576A (ko) 2009-05-06 2019-10-14 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
HK1213886A1 (zh) 2013-04-17 2016-07-15 辉瑞大药厂 用於治療心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT325023B (de) * 1935-11-15 1975-09-25 Boehringer Sohn Ingelheim Verfahren zur herstellung von neuen racemischen oder optisch aktiven n,n'- bis - (3 - subst. phenoxy -2- hydroxy -1- propyl) - alfa, omega - diaminoalkanen sowie deren säureadditionssalzen
GB1078852A (en) * 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
CA956632A (en) * 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
SE372762B (en:Method) * 1969-05-21 1975-01-13 Haessle Ab
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
SE354851B (en:Method) * 1970-02-18 1973-03-26 Haessle Ab
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives

Also Published As

Publication number Publication date
JPS5285146A (en) 1977-07-15
NZ182498A (en) 1978-04-03
ES452920A1 (es) 1977-11-01
FI62829B (fi) 1982-11-30
CH602582A5 (en:Method) 1978-07-31
IE43645L (en) 1977-05-06
BE847801A (fr) 1977-02-14
LU76117A1 (en:Method) 1978-07-10
NO142034C (no) 1980-06-18
DE2649605B2 (de) 1980-07-10
DE2649605C3 (de) 1981-04-02
ATA812076A (de) 1977-12-15
AU1925976A (en) 1978-05-11
US4311708A (en) 1982-01-19
JPS5848543B2 (ja) 1983-10-28
ZA766338B (en) 1977-10-26
AT344683B (de) 1978-08-10
IL50814A (en) 1979-11-30
NL179051C (nl) 1986-07-01
IL50814A0 (en) 1977-01-31
SE433208B (sv) 1984-05-14
DE2649605A1 (de) 1977-05-18
FI763132A7 (en:Method) 1977-05-07
DK495476A (da) 1977-05-07
DK145119C (da) 1983-02-14
PT65780A (fr) 1976-12-01
NO763732L (no) 1977-05-09
SE7612177L (sv) 1977-05-07
IE43645B1 (en) 1981-04-22
FI62829C (fi) 1983-03-10
FR2330383A1 (fr) 1977-06-03
GR61363B (en) 1978-10-30
AR214303A1 (es) 1979-05-31
FR2330383B1 (en:Method) 1979-09-21
PT65780B (fr) 1978-05-10
DK145119B (da) 1982-09-06
NL7612123A (nl) 1977-05-10
GB1515978A (en) 1978-06-28
NO142034B (no) 1980-03-10
NL179051B (nl) 1986-02-03
US4252984A (en) 1981-02-24
CA1072981A (en) 1980-03-04

Similar Documents

Publication Publication Date Title
AU501581B2 (en) Phenol ethers
AU501806B2 (en) Ethers
AU513149B2 (en) Oxime ether
AU503708B2 (en) 2', 4-dichloro-4' - benzoylureido-diphenyl ethers
AU1108376A (en) Polyhemoglobin
AU1025376A (en) Pourer-stopper
AU1006976A (en) Inhilator
AU1230276A (en) Amidinoureas
AU1230176A (en) Imidinoureas
AU1441776A (en) Thieno-pyridines
AU1373876A (en) Bottlecap
AU500738B2 (en) Preparation
AU508904B2 (en) Polyether
AU499514B2 (en) Daunosaminyl anthracyclinones
AU1128976A (en) Magneto-alternator
AU1417076A (en) Propargyl-2 phenylamino-2-impazolines
AU511431B2 (en) 2-substituted-5-alkyl resorcinols
AU507587B2 (en) Substituted benzoyl-ureidodhenyl ethers
AU502167B2 (en) Disubstaituted phenol ethers of 3-amino-2-hydroxypropane
AU1408076A (en) Lysolipin Antibioties
AU1191776A (en) Fluoro-prostaglandins
AU1393076A (en) Dihydromocimycin
AU1398876A (en) Aryl-di-thioureas
AU498636B2 (en) Biphenyl ethers
AU1460876A (en) 6-aminomethylated 3-oxygenated chloest-5-enes